#Singapore #Mona Lisa 2.0 #Biobot Surgical #Prostate Care

Biobot Surgical's Mona Lisa 2.0 Receives CE Certification

Biobot Surgical, a pioneer in robotic-assisted treatment for prostate diseases, is celebrating a significant milestone with the CE certification of its latest innovation, the Mona Lisa 2.0. This certification, combined with existing approvals from the US FDA, Australia's TGA, and Singapore's HSA, paves the way for the Mona Lisa 2.0 to be used in clinical practices across an additional 32 countries in Europe, significantly expanding its reach and impact.

The Mona Lisa 2.0 introduces advanced features that tackle the challenges of prostate biopsies and ablations with remarkable precision, efficiency, and versatility. Here’s a closer look at its standout capabilities:

Precision Targeting and Advanced Positioning

One of the key highlights of the Mona Lisa 2.0 is its advanced positioning system designed specifically for prostate interventional procedures. This system allows real-time adjustments to the prostate model and needle locations based on shifts that may occur during a procedure. Urologists can now maintain accurate targeting, ensuring better outcomes in both diagnostic and therapeutic contexts.

Enhanced Needle Accuracy

Another innovative feature is the adjustment capability for needle deflection. The new software allows doctors to tailor needle trajectories in response to tissue variations and needle tip designs. This tailored approach not only boosts confidence in biopsy reliability but also minimizes risks associated with misalignment, providing more accurate results.

Streamlined Multi-needle Insertions

To enhance workflow, the Mona Lisa 2.0 facilitates efficient multi-needle insertions. This feature reduces manual interventions and boosts operational effectiveness during complex procedures. Coupled with advanced visualization tools, such as overlays of lesion margins and simulated ablation zones, it supports urologists in accurately targeting problematic areas while safeguarding vital structures.

A Game-Changer for European Urology

Albert Lee, CEO of Biobot Surgical, emphasized the significance of this certification: “The CE certification of the Mona Lisa 2.0 is not just a new milestone for us, but a transformative moment for urologists throughout Europe. Its innovative capabilities empower them to provide exceptional patient outcomes.”

With its impressive track record of 25,000 procedures conducted globally on the original Mona Lisa platform, the Mona Lisa 2.0 promises to advance urology practices across the continent. Its introduction is set to enhance patient care quality while optimizing the workflows for healthcare providers.

For more information about the Mona Lisa 2.0 and its availability in Europe, potential users and interested parties can visit biobotsurgical.com or reach out to Grace Phee via email.

About Biobot Surgical

Biobot Surgical stands at the forefront of robotic precision in prostate disease management. Devoted to revolutionizing urology care, the company focuses on developing innovative solutions that equip healthcare professionals to deliver better outcomes. Both the original Mona Lisa and its successor, the Mona Lisa 2.0, have received top-tier regulatory approvals, underscoring the company's commitment to excellence in medical technology.